Home    Back

Wharton's jelly derived mesenchymal stem cell    (DrugBank: -)

1 disease
IDDisease name (Link within this page)Number of trials
90Retinitis pigmentosa1

90. Retinitis pigmentosa    [ 103 clinical trials,   158 drugs,   (DrugBank: 42 drugs),   52 drug target genes,   107 drug target pathways]
Searched query = "Retinitis pigmentosa", "Rod dystrophy", "Rod-Cone Dystrophy"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 103 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT04224207
(ClinicalTrials.gov)		April 1, 20196/1/2020Management of Retinitis Pigmentosa by Mesenchymal Stem Cells by Wharton's Jelly Derived Mesenchymal Stem CellsManagement of Retinitis Pigmentosa by Wharton's Jelly Derived Mesenchymal Stem Cells: Preliminary Clinical ResultsRetinitis Pigmentosa;Inherited Retinal DystrophyBiological: Wharton's jelly derived mesenchymal stem cellAnkara Universitesi TeknokentNULLCompleted18 Years60 YearsAll32Phase 3Turkey